VBC Market Dynamics
Expert articles and analysis related to vbc market dynamics.
AI Summary — Last 30 Days
CMS under the Trump administration is pushing VBC further toward mandatory and episode-based accountability, with expanded joint replacement model participation by 2028 and renewed policy attention to bundled payments, while the 2027 Medicare Physician Fee Schedule proposal and bipartisan Patients First Act signal parallel efforts to stabilize primary care and strengthen accountable care infrastructure. Commercial and MA stakeholders are also repositioning around risk-bearing physician networks, as seen in Millennium Physician Group’s partnership with Franciscan Alliance in Indiana and Aetna’s reported Medicare Advantage VBC gains—evidence that payers and providers are scaling population-health capabilities ahead of tighter payment updates and more downside-risk exposure. The strategic tension for ACOs and health systems is whether they can fund care management, specialist alignment, and post-acute integration fast enough to succeed as CMS expands mandatory models and physician-payment reforms remain politically unsettled (expanded joint replacement model; Patients First Act).
Related Articles
The price of Ozempic is a meaningless phrase
By JOHN SAMARAS Ask what Ozempic costs. The honest answer runs from $25 a month to $1,100 a month, and every number in that range is real, published, and defensible. A phraseContinue reading...
Drug costs are becoming hospitals’ fastest-growing financial threat
Drug costs are becoming hospitals’ fastest-growing financial threat Becker's Hospital Review
FTC Reaches Settlement With CVS Caremark to Curb Insulin Rebate Practices, Cut Patient Costs
AHA challenges HRSA’s burden estimate for proposed 340B rebate model
AHA challenges HRSA’s burden estimate for proposed 340B rebate model American Hospital Association
Glenmark to pay $29.7M in generic drug price-fixing settlement
Glenmark to pay $29.7M in generic drug price-fixing settlement Healthcare Finance News
340B drug purchases hit at least $100B in 2025, administrator reports
340B drug purchases hit at least $100B in 2025, administrator reports Fierce Healthcare
The 340B Rebate Fight Is Really Over Data Infrastructure Nobody Has Built
The 340B Rebate Fight Is Really Over Data Infrastructure Nobody Has Built Health Affairs
AHA Responds to HRSA 340B Rebate Model Pilot Program Information Request
AHA Responds to HRSA 340B Rebate Model Pilot Program Information Request American Hospital Association
STAT+: Glenmark to pay $29.6 million to settle price-fixing allegations in long-running battle with states
Glenmark Pharmaceuticals agreed to pay $29.6 million to settle price-fixing allegations in a long-running battle with dozens of states.
Arbital Health Unveils Self-Serve Actuarial AI Platform for Value-Based Care Risk Management
Arbital Health Unveils Self-Serve Actuarial AI Platform for Value-Based Care Risk Management TipRanks